Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: as-needed fluticasone propionate Clear all
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Management of Recurrent Croup

NCT01748162
View directory record Official record
Conditions
Croup
Interventions
Fluticasone, Prednisolone IF needed
Drug
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 15 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02141854
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
85
States / cities
Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma

NCT00294398
View directory record Official record
Conditions
Asthma
Interventions
ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Individualized Therapy For Asthma in Toddlers

NCT01606306
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
daily fluticasone propionate, Montelukast, as-needed fluticasone propionate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 59 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
13
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes

NCT00521222
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267
View directory record Official record
Conditions
Asthma
Interventions
TEV-56248, Albuterol sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
4 Years and older
Enrollment
2,772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Dothan, Alabama • Paradise Valley, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

NCT01479621
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
129
States / cities
Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

NCT01576718
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

NCT03012061
View directory record Official record
Conditions
Asthma
Interventions
Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

NCT02483975
View directory record Official record
Conditions
Asthma
Interventions
FF, Placebo, Montelukast, Albuterol/Salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 25, 2026, 10:15 AM EDT